24R-Calcipotriol
Based on 1 Customer Validation
24R-Calcipotriol (PRI 2202; Impurity D of Calcipotriol), an isomer of Calcipotriol (HY-10001), is a synthetic vitamin D analog. 24R-Calcipotriol exhibits synergistic antiproliferative effects with low-dose cytostatics in in vitro. 24R-Calcipotriol produces tumor growth inhibition when combined with Cyclophosphamide (HY-17420) and Cisplatin (HY-17394) in mice models. 24R-Calcipotriol can increase serum calcium levels and reduce blood leukocyte counts. 24R-Calcipotriol can be used for the research of mammary cancer and Lewis lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 94.85%
- CAS No.: 112827-99-3
- Formule: C27H40O3
- Masse moléculaire:412.60
-
Stockage:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
24R-Calcipotriol (100 nM; 120 h) produces an additive antiproliferative effect on Lewis lung carcinoma (LLC) cells when combined with 1 μg/mL Cisplatin (HY-17394)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Lewis lung carcinoma (LLC) cells
-
Concentration:100 nM (in combination with 1 μg/mL cisplatin)
-
Incubation Time:120 h
-
Result:Produced an additive antiproliferative effect on LLC cells, contributing to inhibition of cell proliferation.
24R-Calcipotriol (10 μg/kg; s.c.; on days 1, 3, 6, 8, 10, 13, 15, 17 and 20) alone does not significantly reduce LLC tumor volume, and combined with Cisplatin (HY-17394) yields a 52% TGI on day 20, while increasing serum calcium levels and reducing blood leukocyte counts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 12-16 week old, 20-25 g, orthotopic inoculation of 4T1 tumor cells)[1]
-
Dosage:10 μg/kg
-
Administration:s.c.; on days 2, 5, 7, 9, 12, 14, 16, 19 and 21
-
Result:Decreased tumor volume compared to untreated controls.
Significantly increased serum calcium levels compared to mice treated without any vitamin D analog.
Showed no statistically significant difference in the number of lung metastases compared to other vitamin D analog groups.
-
Animal Model:C57BL/6 (male, 12-16 week old, 20-25 g, subcutaneous inoculation of LLC tumor cells)[1]
-
Dosage:10 μg/kg
-
Administration:s.c.; on days 1, 3, 6, 8, 10, 13, 15, 17 and 20
-
Result:Did not reduce tumor volume to levels seen in Cisplatin-treated groups when administered alone.
Achieved 52% tumor growth inhibition (TGI) on day 20 when combined with Cisplatin, a non-statistically significant improvement over cisplatin alone.
Significantly increased serum calcium levels compared to mice treated without any vitamin D analog.
Significantly reduced blood leukocyte levels compared to mice treated without any vitamin D analog.
Chemical Information
-
CAS No. 112827-99-3
-
Appearance Solid
-
Masse moléculaire 412.60
-
Formule C27H40O3
-
Color White to off-white
-
SMILES
O[C@H]1C[C@H](O)C(/C(C1)=C\C=C2[C@]3([H])CC[C@H]([C@H](C)/C=C/[C@@H](C4CC4)O)[C@@]3(C)CCC\2)=C
-
Synonyms
PRI 2202; Impurity D of Calcipotriol
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Solvant et solubilité
DMSO : 100 mg/mL (242.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (645 KB)
- English - EN (645 KB)
- Français - FR (645 KB)
- Deutsch - DE (645 KB)
- Norwegian - NO (645 KB)
- Español - ES (645 KB)
- Swedish - SV (645 KB)
- Italian - IT (645 KB)
- Korean - KR (645 KB)
- Portuguese - PT (645 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4237 mL | 12.1183 mL | 24.2365 mL | 60.5914 mL |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8473 mL | 12.1183 mL | |
| 10 mM | 0.2424 mL | 1.2118 mL | 2.4237 mL | 6.0591 mL | |
| 15 mM | 0.1616 mL | 0.8079 mL | 1.6158 mL | 4.0394 mL | |
| 20 mM | 0.1212 mL | 0.6059 mL | 1.2118 mL | 3.0296 mL | |
| 25 mM | 0.0969 mL | 0.4847 mL | 0.9695 mL | 2.4237 mL | |
| 30 mM | 0.0808 mL | 0.4039 mL | 0.8079 mL | 2.0197 mL | |
| 40 mM | 0.0606 mL | 0.3030 mL | 0.6059 mL | 1.5148 mL | |
| 50 mM | 0.0485 mL | 0.2424 mL | 0.4847 mL | 1.2118 mL | |
| 60 mM | 0.0404 mL | 0.2020 mL | 0.4039 mL | 1.0099 mL | |
| 80 mM | 0.0303 mL | 0.1515 mL | 0.3030 mL | 0.7574 mL | |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.6059 mL |
24R-Calcipotriol Related Classifications
HY-15266 Related Classifications
Powered by Bioz
- 24R-Calcipotriol
- 112827-99-3
- PRI 2202
- Impurity D of Calcipotriol
- PRI2202
- PRI-2202
- Drug Derivative
- VD/VDR
- 4T1 mammary adenocarcinoma model
- Lewis lung cancer
- cyclophosphamide
- cisplatin
- mammary cancer
- Lewis lung carcinoma cells
- hypercalcemia
- tumor-bearing mice
- mouse models
- antiproliferative effects
- Inhibitor
- inhibitor
- inhibit